Halozyme Therapeutics Company Leadership

Halozyme Therapeutics' latest congressional trading

Halozyme Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of 0.1816 % which means that it generated a profit of $0.1816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.9842 %, meaning that it created $1.9842 on every $100 dollars invested by stockholders. Halozyme Therapeutics' management efficiency ratios could be used to measure how well Halozyme Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to grow to 0.37. Also, Return On Capital Employed is likely to grow to 0.30. At this time, Halozyme Therapeutics' Return On Tangible Assets are very stable compared to the past year. As of the 24th of March 2025, Debt To Assets is likely to grow to 0.90, while Other Current Assets are likely to drop about 22.6 M. As of the 24th of March 2025, Net Income Applicable To Common Shares is likely to grow to about 244.1 M, while Common Stock Shares Outstanding is likely to drop about 106.3 M.

Halozyme Therapeutics Workforce Comparison

Halozyme Therapeutics Profit Margins

The company has Profit Margin (PM) of 0.44 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.59 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.59.

Halozyme Therapeutics Insider Trading History

Halozyme Therapeutics Notable Stakeholders

The success or failure of an entity such as Halozyme Therapeutics often depends on how effective the management is. Halozyme Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Halozyme management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Halozyme management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.